Publications by authors named "Daniel J Gironda"
Despite advancements in the early-stage detection and expansion of treatments for prostate cancer (PCa), patient mortality rates remain high in patients with aggressive disease and the overtreatment of indolent disease remains a major issue. Prostate-specific antigen (PSA), a standard PCa blood biomarker, is limited in its ability to differentiate disease subtypes resulting in the overtreatment of non-aggressive indolent disease. Here we assess engorged cancer-associated macrophage-like cells (CAMLs), a ≥50 µm, cancer-specific, polynucleated circulating cell type found in the blood of patients with PCa as a potential companion biomarker to PSA for patient risk stratification.
View Article and Find Full Text PDFBackground: Liquid biopsies have become an integral part of cancer management as minimally invasive options to detect molecular and genetic changes. However, current options show poor sensitivity in peritoneal carcinomatosis (PC). Novel exosome-based liquid biopsies may provide critical information on these challenging tumors.
View Article and Find Full Text PDFArticle Synopsis
- Treatment of colorectal cancer-derived peritoneal carcinomatosis (CRC-PC) is complex due to varying resistance to chemotherapy, leading to frequent recurrences after surgery with HIPEC.
- Patient-derived tumor organoids (PTOs) are highlighted as a promising tool for personalizing treatment strategies based on individual patient characteristics.
- A review of 5 relevant studies found that PTOs are being used to improve therapies and uncover disease mechanisms, but further research is needed to better integrate organoids into patient care.
Background: Cancer Associated Macrophage-Like cells (CAMLs) are polynucleated circulating stromal cells found in the bloodstream of numerous solid-tumor malignancies. Variations within CAML size have been associated with poorer progression free survival (PFS) and overall survival (OS) in a variety of cancers; however, no study has evaluated their clinical significance in esophageal cancer (EC).
Methods: To examine this significance, we ran a 2 year prospective pilot study consisting of newly diagnosed stage I-III EC patients (n = 32) receiving chemoradiotherapy (CRT).